Earnings ·
Rigel Reports Q3 Net Income of $13.2M on $80.9M Revenue, Launches VEPPANU
RIGLRigel Pharmaceuticals Inc
Rigel Pharmaceuticals reported third-quarter 2026 total revenues of $80.9 million, comprising $72.3 million in net product sales and $8.6 million in contract revenues. Net income was $13.2 million, or $0.70 basic per share, compared to $27.9 million in the prior-year period. The results reflect the commercial launch of VEPPANU (vepdegestrant), which generated $6.6 million in initial sales after becoming available in mid-August. TAVALISSE net product sales rose 13% to $46.0 million, while REZLIDHIA and GAVRETO contributed $9.9 million and $9.8 million, respectively. The company updated its full-year revenue outlook to approximately $290–$295 million, excluding VEPPANU sales. Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer.